A ground-breaking study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has revealed crucial insights into the role of the histone methyltransferase NSD2 and its epigenetic target PKCα in causing t(4;14) translocated multiple myeloma (MM), a high-risk subtype of blood cancer, to be more aggressive and resistant to treatment.
Tag: Myeloma
Ketogenic diet and its effects on tumour growth and ‘wasting syndrome’
Professor Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore at the National University of Singapore, together with Assistant Professor Tobias Janowitz, Principal Investigator at the Cold Spring Harbor Laboratory in New York, and an international group of researchers from the USA and UK, have discovered that ketogenic diets delay tumour growth but accelerate cachexia, a wasting syndrome, an unintended side effect that could cause death.
Triple-drug therapy for post-transplant management of multiple myeloma
Promising results from an ongoing clinical trial a three-drug treatment may improve survival in patients with newly diagnosed multiple myeloma who have undergone preliminary treatment followed by a stem cell transplant.
Sylvester Comprehensive Cancer Center Receives Approval to Build World-Class Myeloma Research Institute
The Myeloma Research Institute’s launch follows many important accomplishments by C. Ola Landgren, M.D., Ph.D. and his team, who are dedicated to fulfilling a promise of providing the best cancer care to myeloma patients. Florida is among the states with the highest rates of new myeloma diagnoses in the U.S., with 7.9 cases diagnosed in every 100,000 of the state’s residents.
Blood cancer scientists developing powerful new tools to improve diagnosis and treatment for patients
Australian researchers will use new technology to improve the diagnosis and treatment of blood cancers, which affect 1.24 million people globally, including 720,000 who die from leukemia, lymphoma or myeloma each year.
Caregivers for People with Multiple Myeloma Face Mental Health Challenges
Caregivers for patients with multiple myeloma may suffer from higher rates of anxiety and depression than patients themselves, according to a new study published today in Blood Advances.
MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.
Whole Genome Sequencing Offers New Diagnostic Insights for Multiple Myeloma Precursor Conditions
In a study published in Nature Communications, researchers at Sylvester Comprehensive Cancer Center have shown that whole genome sequencing can help determine which patients with a multiple myeloma precursor condition, called MGUS or smoldering myeloma, progress to full-blown cancer
New CAR T-Cell Therapy Extends Remission In Heavily Relapsed Multiple Myeloma Patients
DALLAS – March 8, 2021 – A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.
Dr. Mohamad Cherry of Atlantic Health System Presents Studies at Top International Blood Cancer Meeting
Dr. Cherry focused on results from a Juno Therapeutics phase 2 study of liso-cel, an investigational CAR T therapy being tested against aggressive relapsed/refractory B cell non-Hodgkin lymphoma. Early results indicate a good safety profile, with few adverse events reported. Dr. Cherry also presented on the final results of a phase 1 study of targeted therapy gilteritinib in newly diagnosed acute myeloid leukemia (AML). Gilteritinib targets the most common mutation that causes AML, the FLT3 gene. Gilteritinib is sold under the brand name Xospata® by Astellas Pharma.
Designer DNA Therapeutic Wipes Out Cancer Stem Cells, Treats Multiple Myeloma in Mice
UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma.
Sequencing Study from Roswell Park Highlights Previously Unknown Myeloma Resistance Mechanisms
— A group of researchers led by Maximillian Merz, MD, Assistant Professor of Oncology with the Myeloma team at Roswell Park Comprehensive Cancer Center, conducted the first prospective clinical trial investigating spatial heterogeneity in patients with either relapsed/refractory or newly diagnosed multiple myeloma. Findings from the study will be presented today at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held virtually.
Dana-Farber Cancer Institute and Quest Diagnostics collaborate to identify the prevalence of COVID-19 in individuals with precursor to multiple myeloma
Dana-Farber Cancer Institute, one of the world’s leading centers of cancer research and treatment, and Quest Diagnostics, (NYSE: DGX), the world’s leading provider of diagnostic information services, announced the start of a new research study that provides free COVID-19 antibody testing to individuals who are at high risk of developing multiple myeloma.
MD Anderson and Allogene Therapeutics announce strategic collaboration to accelerate advancement of allogeneic CAR T therapy (AlloCAR T)
MD Anderson and Allogene today announced a strategic five-year collaboration for preclinical and clinical investigation of allogeneic CAR T cell therapies.
Robbins Family Awards Honor Exemplary Service In Nursing at Memorial Sloan Kettering
As we celebrate National Nurses Week, Memorial Sloan Kettering Cancer Center (MSK) and The Robbins Family Foundation recognize seven distinguished nursing staff members for their exemplary service. Each member of this select group is being honored with the inaugural 2020 Robbins Family Award for Nursing Excellence.
Dana-Farber Cancer Institute to Establish Riney Family Multiple Myeloma Initiative
Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.
BCMA-Targeted Immunotherapy Can Lead to Durable Responses in Multiple Myeloma
An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies